MX2017005243A - Reducción de la viscosidad de formulaciones farmacéuticas. - Google Patents

Reducción de la viscosidad de formulaciones farmacéuticas.

Info

Publication number
MX2017005243A
MX2017005243A MX2017005243A MX2017005243A MX2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A MX 2017005243 A MX2017005243 A MX 2017005243A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulations
reducing viscosity
acetyl
viscosity
pharmaceutical formulation
Prior art date
Application number
MX2017005243A
Other languages
English (en)
Other versions
MX388858B (es
Inventor
James Sloey Christopher
KANAPURAM Sekhar
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005243(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017005243A publication Critical patent/MX2017005243A/es
Publication of MX388858B publication Critical patent/MX388858B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un método para reducir la viscosidad de una formulación farmacéutica que utiliza una concentración de reducción de la viscosidad de un excipiente seleccionado del grupo que consiste de la n-acetil arginina, n-acetil lisina, n-acetil prolina y mezclas de los mismos en combinación con una proteína terapéutica. También se proporciona una formulación farmacéutica estable.
MX2017005243A 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas MX388858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23
PCT/US2015/056972 WO2016065181A1 (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Publications (2)

Publication Number Publication Date
MX2017005243A true MX2017005243A (es) 2017-08-18
MX388858B MX388858B (es) 2025-03-20

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005243A MX388858B (es) 2014-10-23 2015-10-22 Reducción de la viscosidad de formulaciones farmacéuticas
MX2021015789A MX2021015789A (es) 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015789A MX2021015789A (es) 2014-10-23 2017-04-21 Reduccion de la viscosidad de formulaciones farmaceuticas.

Country Status (17)

Country Link
US (3) US11813328B2 (es)
EP (2) EP3209332B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN114569716A (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA038462B1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B2 (es)
MA (1) MA54716A (es)
MX (2) MX388858B (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
ES3036143T3 (en) * 2017-04-28 2025-09-15 Amgen Inc N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
WO2018200533A1 (en) 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
DK3881861T3 (da) 2017-06-16 2024-09-09 Zealand Pharma As Doseringsregimer for indgivelse af glukagonlignende peptid-2- (GLP-2)-analoger
JP6577683B2 (ja) * 2017-09-22 2019-09-18 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
US20210292434A1 (en) 2018-07-05 2021-09-23 Bayer Aktiengesellschaft NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20220226477A1 (en) * 2019-04-23 2022-07-21 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations
KR20220140772A (ko) * 2020-02-13 2022-10-18 암젠 인크 인간 항-tslp 항체 제형 및 염증성 질환의 치료 방법
KR102746418B1 (ko) * 2020-12-03 2024-12-26 동국대학교 산학협력단 N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물
EP4306103B1 (en) * 2021-03-09 2025-12-24 GI Innovation, Inc. Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor
EP4319795A4 (en) * 2021-04-09 2025-03-05 Avantor Performance Materials, LLC Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations
WO2025175164A1 (en) * 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
JP2001522814A (ja) * 1997-11-07 2001-11-20 カイロン コーポレイション 増大されたｉｇｆ−ｉ溶解性を提供する組成物
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
EP1273306A4 (en) * 2000-03-31 2005-06-22 Kirin Brewery POWDER PREPARATION FOR TRANSMUCOSAL ADMINISTRATION CONTAINING A POLYMERIC FORM OF AN ACTIVE SUBSTANCE AND HAVING AN IMPROVED STORAGE STABILITY
WO2002038170A2 (en) 2000-11-07 2002-05-16 Chiron Corporation Stabilized inteferon compositions
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
MX2009006471A (es) 2006-12-14 2009-06-26 Schering Corp Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
AR067045A1 (es) 2007-06-20 2009-09-30 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
BRPI0907186A2 (pt) * 2008-01-15 2015-07-14 Abbott Gmbh & Co Kg Composições proteicas pulverizadas e métodos para sua produção
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제
CA2788863C (en) 2010-02-04 2020-07-07 Csl Behring Ag Immunoglobulin preparation
CN107496917B (zh) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
WO2011109415A2 (en) 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
RU2012151500A (ru) * 2010-05-03 2014-06-10 Дженентек, Инк. Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN104023748B (zh) * 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
MX388043B (es) 2014-12-03 2025-03-19 Csl Behring Ag Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas.
CA3038909A1 (en) 2016-09-29 2018-04-05 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
WO2018067987A1 (en) 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
EA038462B1 (ru) 2021-08-31
US20240066124A1 (en) 2024-02-29
MX388858B (es) 2025-03-20
CL2019002190A1 (es) 2019-11-22
AU2021200990A1 (en) 2021-03-11
CN114569716A (zh) 2022-06-03
EA033444B1 (ru) 2019-10-31
JP2017531682A (ja) 2017-10-26
MX2021015789A (es) 2022-01-27
WO2016065181A1 (en) 2016-04-28
AU2015335743B2 (en) 2020-12-24
EP3909611B1 (en) 2023-08-30
CA2964786A1 (en) 2016-04-28
CL2017000984A1 (es) 2018-01-05
IL251726A0 (en) 2017-06-29
IL287947B2 (en) 2024-08-01
AU2021200990B2 (en) 2023-02-16
CN107206070A (zh) 2017-09-26
EP3909611A1 (en) 2021-11-17
EA201790787A1 (ru) 2017-08-31
EP3209332B1 (en) 2021-05-26
ES2964713T3 (es) 2024-04-09
KR20170071518A (ko) 2017-06-23
AU2015335743A1 (en) 2017-05-04
JP2022009223A (ja) 2022-01-14
CN107206070B (zh) 2022-01-18
US11813328B2 (en) 2023-11-14
BR112017008125B1 (pt) 2023-11-21
EA202191513A1 (ru) 2021-11-30
EP3209332A1 (en) 2017-08-30
EA201991447A1 (ru) 2019-11-29
KR102534017B1 (ko) 2023-05-19
CA2964786C (en) 2023-10-17
IL287947B1 (en) 2024-04-01
IL287947A (en) 2022-01-01
IL251726B (en) 2021-12-01
JP2020037559A (ja) 2020-03-12
ZA201702762B (en) 2022-12-21
JP7411615B2 (ja) 2024-01-11
SG11201703152RA (en) 2017-05-30
BR112017008125A2 (pt) 2018-06-19
US20170333559A1 (en) 2017-11-23
US12318447B2 (en) 2025-06-03
JP6965321B2 (ja) 2021-11-10
MA54716A (fr) 2021-11-17
US20250345421A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
MX2017005243A (es) Reducción de la viscosidad de formulaciones farmacéuticas.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201592106A3 (ru) Локальное сопутствующее введение толерогенных синтетических наноносителей для снижения гиперчувствительности типа i и гиперчувствительности типа iv
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
AR092219A1 (es) Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
CL2015002897A1 (es) Inhibidores de bace1
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
MX2017011018A (es) Inhibicion de la actividad de olig2.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino